Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 26, 2016Two other Eisai-marketed products -- HALAVEN® (eribulin mesylate) and BELVIQ® (lorcaserin HCI) CIV -- also collect nominations
Eisai Inc. announced today that LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor (TKI), has been nominated for Best Pharmaceutical Product at the 10th Annual Prix...
- Oct 26, 2016"Medikidz Explain LGS," endorsed by leading advocacy groups, educates public on rare and severe form of epilepsy
Eisai Inc. today announced the launch of "Medikidz Explain Lennox-Gastaut Syndrome (LGS)," an educational comic book designed to inform people about LGS, a rare type of epilepsy that is usually...
- Oct 26, 2016
Eisai Inc. and the Oklahoma Medical Research Foundation (OMRF) have formed a research collaboration to study the autoimmune disease lupus. Under the new agreement, Eisai's research team at its...
-
Oct 13, 2016Study Evaluated Maximum Tolerated Dose
Eisai Inc. announced today the presentation of preliminary results of a Phase 1b clinical study (Study 111) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib...
- Oct 3, 2016New FDA-Approved Formulation Offers Patients a Once-Daily Dosing Option for Chronic Weight Management
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that...
